Business
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results
Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to planCo-developing 3D bioprinted human
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to planCo-developing 3D bioprinted human intestine model (\"Gut-on-a-Chip\") for drug discovery and personalized treatment of ulcerative colitis with Tel-Aviv University and SHEBA Hospital3D bioprinted regenerative breast implant program on track for Q1 2023 readout of large animal studyBioink platform expanded with recent launch of Collink.3D™ 90 to offer additional functionality and performance benefits of biofabricated constructsStrong balance sheet with cash and cash equivalents of $33M as of September 30, 2022REHOVOT, Israel, Dec. 1, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2022 and provided an update on the Company's business developments.\n\n \n \n \n \n \n \n\n \n\"CollPlant made significant progress this quarter with our development partners to advance and diversify our product portfolio, which is targeting large commercial opportunities in both existing and new markets, including medical aesthetics and personalized medicine,\" said Yehiel Tal, CollPlant's CEO. \"Our long-term collaboration with AbbVie to develop what has the potential to be a paradigm-shifting dermal and soft tissue filler, which utilizes rhCollagen to deliver better tissue regeneration performance, continues to move forward according to plan. We also recently announced a partnership with Tel Aviv University and SHEBA Hospital to develop a 3D bioprinted model of the human intestine. We believe this product will be of great interest to biopharma companies to support drug discovery, helping to identify new drug candidates, as well as personalized therapeutic treatments for ulcerative colitis.\"\n\"We are also enthusiastic with the progress and potential of our internal pipeline, including the development of a next generation photocurable dermal filler technology for use in soft tissue indications such as facial contouring. We also recently launched our second bioink, Collink.3D™ 90, which is designed to address a wider range of 3D bioprinting applications, such as soft and hard tiss...